Excellent
Partially Aligned
Patient Risk:
Moderate
Summary
The embryo-fetal harm and pregnancy risk/consequences are supported by the label’s Embryo-Fetal Toxicity and Pregnancy risk-summary. The statements about “not recommended during pregnancy” and the absence of fetal-development study results are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Lurbinectedin can cause embryo-fetal harm.
Section 5.5 Embryo-Fetal Toxicity: “ZEPZELCA can cause fetal harm when administered to a pregnant woman.” Also supported by Section 8.1: “ZEPZELCA can cause fetal harm…”
Lurbinectedin is not recommended during pregnancy.
Partially supported/implicit: Section 8.1 states “There are no available data to inform the risk of ZEPZELCA use in pregnant women” and Section 5.5 describes embryo-fetal risk; however, the provided excerpts do not explicitly say “not recommended.”
Unsupported Statements
Lurbinectedin is not recommended during pregnancy.
The provided label excerpts describe embryo-fetal risk and advise patients, but do not explicitly state that lurbinectedin is “not recommended” during pregnancy.
No fetal development (embryo-fetal development) studies in pregnant animals are described in the provided information for lurbinectedin.
The provided excerpts do not include information about animal embryo-fetal development studies; thus this specific “no studies described” claim cannot be verified from the supplied label text.
No human fetal-development study results are included in the provided information for lurbinectedin.
Section 8.1 says there are “no available data to inform the risk… in pregnant women,” but the claim is broader (“no human fetal-development study results”) and is not explicitly stated as such in the provided excerpts.
Contradictions
Important Omissions
If the intent is to describe pregnancy counseling/contraception duration and specific recommendations, those details are present in the label (Section 5.5 and 8.3) but were not included in the AI claims provided.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Embryo-fetal harm is correctly stated, but “not recommended during pregnancy” is not explicitly supported by the provided label excerpts. The study-absence claims are also not verifiable from the supplied text, potentially leading to overconfident interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Two claims (“not recommended during pregnancy” and the specific absence of fetal-development study results) are not explicitly supported by the provided label excerpts.
Suggested Improvement
Replace “not recommended during pregnancy” with label-supported language about fetal harm risk and counseling. If discussing evidence gaps, align to Section 8.1 wording: “There are no available data to inform the risk… in pregnant women.”